Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects | Zendy

Merja Kirjavainen | Zendy; Leena Mattila | Zendy; Mikko Vahteristo | Zendy; Jani Korhonen | Zendy; Satu Lähelmä | Zendy

Open Access

Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects

Author(s) -

Merja Kirjavainen,

Leena Mattila,

Mikko Vahteristo,

Jani Korhonen,

Satu Lähelmä

Publication year - 2018

Publication title -

journal of aerosol medicine and pulmonary drug delivery

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.678

H-Index - 68

eISSN - 1941-2703

pISSN - 1941-2711

DOI - 10.1089/jamp.2017.1437

Subject(s) - salmeterol , fluticasone propionate , cmax , fluticasone , bioequivalence , pharmacokinetics , medicine , pharmacology , crossover study , dry powder inhaler , bronchodilator , inhalation , inhaler , asthma , anesthesia , alternative medicine , pathology , placebo

Easyhaler ® dry powder inhaler (DPI) containing salmeterol and fluticasone propionate was developed for the treatment of asthma and chronic obstructive pulmonary disease. Three different Salmeterol/fluticasone Easyhaler test products (Orion Pharma, Finland) were compared against the reference product Seretide ® Diskus ® DPI (GlaxoSmithKline, United Kingdom) to study whether any of the test products are bioequivalent with the reference.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research